IP Library Granted Patent US 10,626,086
Granted Patent B2
US 10,626,086 · App. 16/361,386 · Granted Apr 21, 2020

Process for the preparation of isosulfan blue

Inventors: Ravishanker Kovi (Monroe, NJ); Satyam Nampalli (Hunt Valley, MD); Peter Xavier Tharial (Edison, NJ)
Assignee: Apicore US LLC
C07C309/46C07C303/02C07C303/22
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,626,086
App. No.
16/361,386
Granted
Apr 21, 2020
Kind
B2
Abstract

Isosulfan blue and processes for the preparation thereof are provided. A process is also provided for preparation of the intermediate, 2-chlorobenzaldehyde-5-sulfonic acid, sodium salt of formula (2), used in the preparation thereof and a procedure for the isolation of benzaldehyde-2,5-disulfonic acid, di-sodium salt of the formula (3). Also provided is a process for the preparation of an isoleuco acid of formula (4), which upon oxidation gives rise to isosulfan blue of pharmaceutical grade which can be used for preparation of pharmaceutical formulations. The isolation and purification procedures provided in the process provide substantially pure isosulfan blue with HPLC purity 99.5% or greater.

Claims (14)

1. A compound isosulfan blue acid or a pharmaceutically acceptable salt thereof having a purity of at least 99.0% by HPLC.

2. The compound according to claim 1 having less than 20 ppm silver.

3. The compound according to claim 1 having a purity between 99.0% and 99.5% by HPLC.

4. The compound according to claim 1 having a purity greater than 99.5% by HPLC.

5. The compound according to claim 4 having less than 20 ppm silver.

6. A pharmaceutical formulation comprising the compound of claim 1 and a pharmaceutically acceptable excipient wherein the pharmaceutical formulation is a solution suitable for parenteral use.

7. The pharmaceutical formulation of claim 6 , wherein the solution is an aqueous solution.

8. The pharmaceutical formulation of claim 6 , wherein the pharmaceutical formulation contains between 0.5% and 1% impurities by HPLC.

9. The pharmaceutical formulation of claim 6 , wherein the pharmaceutical formulation contains less than about 0.5% impurities by HPLC.

10. The pharmaceutical formulation of claim 6 , wherein the pharmaceutical formulation contains less than 20 ppm silver.

11. The compound according to claim 1 prepared by a process comprising combining isolueco acid of formula (4)

with a mild oxidizing agent.

12. The compound according to claim 11 , wherein the process is a large-scale cGMP process.

13. The compound according to claim 11 , wherein the process is a bulk scale process.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 4, 2021
From: MYLAN API US LLC
To: MYLAN INSTITUTIONAL LLC
Reel/Frame 057686/0088 →
CHANGE OF NAME Recorded Oct 4, 2021
From: APICORE US LLC
To: MYLAN API US LLC
Reel/Frame 057697/0758 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 23, 2019
From: KOVI, RAVISHANKER; NAMPALLI, SATYAM; THARIAL, PETER XAVIER
To: APICORE LLC
Reel/Frame 050799/0744 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 23, 2019
From: APICORE LLC
To: APICORE US LLC
Reel/Frame 050800/0690 →
Continuity (7)
Continuation 15801585 · Nov 2, 2017
Continuation 15095791 · Apr 11, 2016
Continuation 13310019 · Dec 2, 2011
Continuation 12643056 · Dec 21, 2009
Continuation 12180057 · Jul 25, 2008
Continuation 11747291 · May 11, 2007
Related Publication 20190218177A1 · Jul 18, 2019